M. Bektaş Et Al. , "Combination therapy of high-dose intravenous anakinra and baricitinib in patients with critical COVID-19: Promising results from retrospective observational study.," International immunopharmacology , vol.129, pp.111586, 2024
Bektaş, M. Et Al. 2024. Combination therapy of high-dose intravenous anakinra and baricitinib in patients with critical COVID-19: Promising results from retrospective observational study.. International immunopharmacology , vol.129 , 111586.
Bektaş, M., Ay, M., Hamdi Uyar, M., & İkbal Kılıç, M., (2024). Combination therapy of high-dose intravenous anakinra and baricitinib in patients with critical COVID-19: Promising results from retrospective observational study.. International immunopharmacology , vol.129, 111586.
Bektaş, Murat Et Al. "Combination therapy of high-dose intravenous anakinra and baricitinib in patients with critical COVID-19: Promising results from retrospective observational study.," International immunopharmacology , vol.129, 111586, 2024
Bektaş, Murat Et Al. "Combination therapy of high-dose intravenous anakinra and baricitinib in patients with critical COVID-19: Promising results from retrospective observational study.." International immunopharmacology , vol.129, pp.111586, 2024
Bektaş, M. Et Al. (2024) . "Combination therapy of high-dose intravenous anakinra and baricitinib in patients with critical COVID-19: Promising results from retrospective observational study.." International immunopharmacology , vol.129, p.111586.
@article{article, author={Murat BEKTAŞ Et Al. }, title={Combination therapy of high-dose intravenous anakinra and baricitinib in patients with critical COVID-19: Promising results from retrospective observational study.}, journal={International immunopharmacology}, year=2024, pages={111586} }